NEW YORK (GenomeWeb News) — Genomic Health today said it hopes to net around $43.3 million in a public stock offering.
 
News of the planned sale caused shares in the company to trade up 7.8 percent at $16.92 in afternoon trading on the Nasdaq exchange.
 
Genomic Health, which makes the Oncotype Dx breast cancer recurrence test, said it would use the cash to expand its marketing capabilities, fund R&D, and expand its lab operations.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.